Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


@@#116300@@

European Psychiatry
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 14 septembre 2011
Doi : 10.1016/j.eurpsy.2011.06.008
Received : 19 February 2010 ;  accepted : 28 June 2011
A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia
 

J. Peuskens a, ⁎ , C. Bervoets b, F. Kok c, B. Delatte d, G. Touquet e, B. Gillain f, A. de Patoul g, V. Halkin g, J.-Y. Loze h, K. Vansteelandt a, E. Constant i
a Universitair Centrum Sint Jozef, Kortenberg, Belgium 
b Polykliniek Onze Lieve Vrouw Sint Michiels, Brugge, Belgium 
c MSOURCE, Lange Dreef 11H, 4131 NJ Vianen, The Netherlands 
d Institut psychiatrique du Beau-Vallon, Saint-Servais, Belgium 
e Psychiatrisch Ziekenhuis Heilig Hart, Ieper, Belgium 
f Cliniques Saint-Pierre, Ottignies, Belgium 
g Bristol-Myers Squibb, parc de l’Alliance, Braine-l’Alleud, Belgium 
h Otsuka pharmaceutical, Rueil-Malmaison cedex, France 
i Cliniques universitaires Saint-Luc, Bruxelles, Belgium 

Corresponding author. Tel.: +32 2 758 05 46; fax: +32 2 758 18 78.
Abstract
Purpose

The aim of this study is to evaluate the effectiveness of 12-week treatment with aripiprazole in a broad range of patients suffering from schizophrenia by using a variety of physicians, caregivers and patients scales.

Subjects and methods

A total of 361 in- or outpatients who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia received open-label aripiprazole (10–30mg per day) in this 12-week, prospective, multicentre, uncontrolled study. The primary endpoint was the Clinical Global Impression-Improvement (CGI-I) scale which measured effectiveness of study medication, including efficacy, safety and tolerability. A variety of physician-, patient- and caregiver-rated parameters were measured to gain a complete view of the effectiveness of aripiprazole.

Results

The effectiveness of aripiprazole treatment was demonstrated in a broad range of schizophrenia patients (CGI-I score of 3.0; 95% confidence interval: 2.8, 3.2: last observation carried forward [LOCF]) as the upper bound of the 95% CI was less than 4 (score of “no change”). Both patient and caregiver PGI-I scores (LOCF: 95% CI: 2.79, 3.09 and, 95% CI: 2.74, 3.17, respectively) corroborate this finding. Aripiprazole had a positive effect on disease severity by study end, as assessed by an increase of the (physician-rated) CGI-S scores, with 57.3% of patients having improved disease, one-third maintaining their condition (30.8%) and 11.3% with worsening symptoms (LOCF). The Investigator Assessment Questionnaire (IAQ) showed a great improvement (>50% of patients). Patients reported significantly improved quality of life and overall, 71% of patients and 67% of caregivers preferred aripiprazole to their previous antipsychotic medication (LOCF; P <0.0001 over time).

Conclusion

Aripiprazole was effective in a broad range of patients with schizophrenia.


Keywords : Aripiprazole, Effectiveness, Schizophrenia


OutlineMasquer le plan
Introduction
Subjects and methods  (+)
Results  (+)
Discussion
Conclusion
Disclosure of interest


© 2011  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline